---
title: "Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults: Safety questions"
description: "Safety questions on Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Side effects. Questions: What are the most common side effects of Prevnar 20 in adults? Prevnar 20 vs Prevnar 13: how common were side effects in Study 1? How common are Prevnar 20 side effects in previously vaccinated adults 65+? How common were serious adverse events with Prevnar 20 in adult trials? 1 further question follow. 5 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/safety"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) in pneumococcal disease prevention in adults: Safety questions

Manufacturer: Wyeth Pharmaceutical Division of Wyeth Holdings LLC  
Prescribing information: [Prevnar 20](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428)

Safety questions that apply to every indication of Prevnar 20 are on [Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine), all indications: Safety](https://www.evicenter.com/medical-information/prevnar-20/safety).

## Side effects

<a id="prevnar20-side-effects"></a>

### What are the most common side effects of Prevnar 20 in adults?

> “In individuals 18 through 59 years of age, the most commonly reported solicited adverse reactions >10% were pain at the injection site (>70%), muscle pain (>50%), fatigue (>40%), headache (>30%), and arthralgia and injection site swelling (>10%).”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=years%20of%20age%29.-,In%20individuals%2018%20through%2059%20years%20of%20age%2C%20the%20most,and%20injection%20site%20swelling%20%28%3E10%25%29.)

> “In individuals 60 years of age and older, the most commonly reported solicited adverse reactions >10% were pain at the injection site (>50%), muscle pain and fatigue (>30%), headache (>20%), and arthralgia (>10%).”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=site%20swelling%20%28%3E10%25%29.-,In%20individuals%2060%20years%20of%20age%20and%20older%2C%20the%20most,headache%20%28%3E20%25%29%2C%20and%20arthralgia%20%28%3E10%25%29.)

<a id="prevnar20-study1-side-effects"></a>

### Prevnar 20 vs Prevnar 13: how common were side effects in Study 1?

> “Percentage of participants in Study 1 with solicited adverse reactions within 7-10 days after vaccination in pneumococcal vaccine-naïve adults<sup>1*</sup>
>  	18-49 Years of Age	50-59 Years of Age	≥60 Years of Age
> Local reaction<sup>†</sup>	Prevnar 20 (n <sup>‡</sup>=335) %	PCV13 (n <sup>‡</sup>=112) %	Prevnar 20 (n <sup>‡</sup>=331) %	PCV13 (n <sup>‡</sup>=111) %	Prevnar 20/Saline (n <sup>‡</sup>=1505) %	PCV13/ PPSV23 (n <sup>‡</sup>=1483) %
> Pain at injection site<sup>§</sup>	81.2	82.1	72.5	69.4	55.4	54.1
> Swelling (>2.0 cm)<sup>§‖‖</sup>	11.6	12.5	8.8	10.8	7.5	8.0
> Redness (>2.0 cm)<sup>§‖‖</sup>	9.0	9.8	8.2	5.4	7.3	6.2
> Any local reaction<sup>¶</sup>	81.2	82.1	72.8	70.3	57.4	56.0
>  	18-49 Years of Age	50-59 Years of Age	≥60 Years of Age
> Systemic reaction<sup>†</sup>	Prevnar 20 (n <sup>‡</sup>=335) %	PCV13 (n <sup>‡</sup>=112) %	Prevnar 20 (n <sup>‡</sup>=331) %	PCV13 (n <sup>‡</sup>=111) %	Prevnar 20/Saline (n <sup>‡</sup>=1505) %	PCV13/ PPSV23 (n <sup>‡</sup>=1483) %
> Muscle pain**	66.6	74.1	49.8	49.5	39.1	37.3
> Fatigue**	42.7	43.8	39.3	36.0	30.2	30.7
> Headache**	38.8	33.9	32.3	36.0	21.5	23.3
> Joint pain**	13.4	17.9	15.4	20.7	12.6	13.7
> Fever (≥38.0 ˚C)	1.2	1.8	1.5	0.9	0.9	0.8
> Any systemic reaction<sup>††</sup>	79.4	83.0	69.5	67.6	55.2	55.4
> Use of antipyretic or pain medication<sup>‡‡</sup>	25.7	23.2	24.5	27.9	18.5	20.4”

Source: [PREVNAR 20: Study 1 Safety, captured 2026-11-13](https://prevnar20adult.pfizerpro.com/clinical-studies/study-1-safety#:~:text=Percentage%20of%20participants%20in%20Study,20.4)

> “Study 1 was conducted in the U.S. and in Sweden.
> Local reactions measured within 10 days after vaccination; systemic reactions measured within 7 days after vaccination.
> n=number of participants with any e-diary data reported after vaccination (after Vaccination 1 [Prevnar 20 or PCV13] for Study 1 participants age 60 or older). This value is the denominator for the percentage calculations.
> Includes all participants who reported a reaction as mild, moderate, or severe during Day 1 to Day 10 after vaccination.
> Diameters were measured in caliper units (0.5 cm) of whole numbers from 1 to 21 or 21+. Measurements were rounded up to the nearest whole number. Intensity of redness and swelling was characterized as: mild is >2.0 to 5.0 cm; moderate is >5.0 to 10.0 cm; severe is >10.0 cm.
> “Any local reaction” includes all participants who reported any injection site reaction (pain, swelling, or redness) as mild, moderate, or severe during Day 1 to Day 10 after vaccination.
> Includes all participants who reported a reaction as mild, moderate, or severe during Day 1 to Day 7 after vaccination.
> “Any systemic reaction” includes all participants who reported any fever ≥38 °C or any other systemic reaction (fatigue, headache, joint pain, or muscle pain) as mild, moderate, or severe during Day 1 to Day 7 after vaccination.
> Severity was not collected for use of antipyretic or pain medication. The numbers listed reflect “yes” responses (ie, number of reactions reported).”

Source: [PREVNAR 20: Study 1 Safety, captured 2026-11-13](https://prevnar20adult.pfizerpro.com/clinical-studies/study-1-safety#:~:text=Study%201%20was%20conducted%20in,%28ie%2C%20number%20of%20reactions%20reported%29.)

Note: The column headings Prevnar 20/Saline and PCV13/PPSV23 refer to the Study 1 design for participants 60 years and older, who received Prevnar 20 followed 1 month later by saline placebo or Prevnar 13 followed 1 month later by PPSV23 (Prescribing Information, section 14.3).

<a id="prevnar20-study6-side-effects"></a>

### How common are Prevnar 20 side effects in previously vaccinated adults 65+?

Applies to: Adults 65 years of age and older previously vaccinated with a pneumococcal vaccine (Study 6)

> “Percentage of participants in Study 6 with solicited adverse reactions within 7-10 days after vaccination in adults age 65 or older with prior pneumococcal vaccination<sup>1*†</sup>
>  	PRIOR PPSV23<sup>‡</sup>	PRIOR PCV13<sup>‡</sup>	PRIOR PCV13 and PPSV23<sup>‡</sup>
> Local reaction<sup>§</sup>	Prevnar 20 (n <sup>‖‖</sup>=253) %	PCV13 (n <sup>‖‖</sup>=121) %	Prevnar 20 (n <sup>‖‖</sup>=245) %	PPSV23 (n <sup>‖‖</sup>=126) %	Prevnar 20
> (n <sup>‖‖</sup>=125)
> %
> Pain at injection
> site<sup>¶</sup>	50.2	43.0	61.2	56.3	52.8
> Swelling (>2.0 cm)<sup>¶**</sup>	9.9	6.6	9.4	14.3	4.0
> Redness (>2.0 cm)<sup>¶**</sup>	7.9	2.5	8.6	12.7	4.8
> Any local reaction<sup>††</sup>	53.0	43.8	64.1	57.9	54.4
>  	PRIOR PPSV23<sup>‡</sup>	PRIOR PCV13<sup>‡</sup>	PRIOR PCV13 and PPSV23<sup>‡</sup>
> Systemic reaction<sup>§</sup>	Prevnar 20 (n <sup>‖</sup>=253) %	PCV13 (n <sup>‖</sup>=121) %	Prevnar 20 (n <sup>‖</sup>=245) %	PPSV23 (n <sup>‖</sup>=126) %	Prevnar 20
> (n <sup>‖</sup>=125)
> %
> Muscle pain<sup>‡‡</sup>	32.0	31.4	33.9	46.0	37.6
> Fatigue<sup>‡‡</sup>	28.9	23.3	31.0	33.3	32.8
> Headache<sup>‡‡</sup>	17.8	18.2	13.5	21.4	19.2
> Joint pain<sup>‡‡</sup>	6.7	10.7	11.8	15.9	16.8
> Fever (≥38.0 ˚C)	0.8	0.0	0.0	1.6	0.0
> Any
> systemic reaction<sup>§§</sup>	51.8	43.8	50.2	59.5	52.8
> Use of antipyretic
> or pain medication<sup>‖‖‖‖</sup>	15.8	14.9	17.1	19.8	17.6”

Source: [PREVNAR 20: Study 6 Safety, captured 2026-11-13](https://prevnar20adult.pfizerpro.com/clinical-studies/study-6-safety#:~:text=Percentage%20of%20participants%20in%20Study,17.6)

> “Study 6 was conducted in the U.S. and in Sweden.
> Open-label administration of Prevnar 20.
> Includes participants who previously received either PPSV23 ≥1 to ≤5 years before enrollment, PCV13 ≥6 months before enrollment, or PCV13 followed by PPSV23 ≥1 year before enrollment in the study.
> Local reactions measured within 10 days after vaccination; systemic reactions measured within 7 days after vaccination.
> n=number of participants with any e-diary data reported after vaccination. This value is the denominator for the percentage calculations.
> Includes all participants who reported a reaction as mild, moderate, or severe during Day 1 to Day 10 after vaccination.
> Diameters were measured in caliper units (0.5 cm) of whole numbers from 1 to 21 or 21+. Measurements were rounded up to the nearest whole number. Intensity of redness and swelling was characterized as: mild is >2.0 to 5.0 cm; moderate is >5.0 to 10.0 cm; severe is >10.0 cm.
> “Any local reaction” includes all participants who reported any injection site reaction (pain, swelling, or redness) as mild, moderate, or severe during Day 1 to Day 10 after vaccination.
> Includes all participants who reported a reaction as mild, moderate, or severe during Day 1 to Day 7 after vaccination.
> ”Any systemic reaction” includes all participants who reported any fever ≥38 °C or any other systemic reaction (fatigue, headache, joint pain, or muscle pain) as mild, moderate, or severe during Day 1 to Day 7 after vaccination.
> Severity was not collected for use of antipyretic or pain medication. The numbers listed reflect “yes” responses (ie, number of reactions reported).”

Source: [PREVNAR 20: Study 6 Safety, captured 2026-11-13](https://prevnar20adult.pfizerpro.com/clinical-studies/study-6-safety#:~:text=Study%206%20was%20conducted%20in,%28ie%2C%20number%20of%20reactions%20reported%29.)

<a id="prevnar20-serious-adverse-events"></a>

### How common were serious adverse events with Prevnar 20 in adult trials?

> “The safety of a single dose of Prevnar 20 in individuals 18 years of age and older was evaluated in 6 randomized, active-controlled, multicenter clinical trials and one open-label, multicenter clinical trial. All of the trials were conducted in the United States and 2 of the trials also enrolled participants (N=172) in Sweden. Across the 7 trials, 6343 individuals received Prevnar 20 and 2496 received active control vaccine.”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=The%20safety%20of%20a%20single,2496%20received%20active%20control%20vaccine.)

> “Across studies 1 through 6, performed in individuals of all ages, naïve to and with prior pneumococcal vaccination, the proportion of participants reporting 1 or more SAEs within 6 months after vaccination with Prevnar 20 was 1.5% (67 of 4552 participants). This was similar to the proportion of participants with SAEs after vaccination with Prevnar 13 or other applicable control vaccine (1.8%, 44 of 2496). The proportions of participants with SAEs occurring within 1 month after vaccination with Prevnar 20 or with Prevnar 13 or other applicable control vaccine were both 0.4% (19 of 4552 participants and 11 of 2496 participants, respectively). There were no notable patterns or imbalances between vaccine groups for specific categories of serious adverse events that would suggest a causal relationship to Prevnar 20.”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=Across%20studies%201%20through%206%2C,causal%20relationship%20to%20Prevnar%2020.)

<a id="prevnar20-prevnar-13-postmarketing"></a>

### Which Prevnar 13 postmarketing side effects may also occur with Prevnar 20?

Applies to: Prevnar 13 postmarketing reports that the label states may also be seen with Prevnar 20

> “The postmarketing safety experience with Prevnar 13 in individuals 6 weeks of age and older is relevant to Prevnar 20 since the vaccines are manufactured and formulated similarly and contain 13 of the same polysaccharide conjugates. These adverse reactions are included based on one or more of the following factors: severity, frequency of reporting, or strength of evidence for a causal relationship to Prevnar 13 vaccine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to product exposure. The following adverse reactions have been spontaneously reported during postapproval use of Prevnar 13 and may also be seen in postmarketing experience with Prevnar 20.”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=The%20postmarketing%20safety%20experience%20with,postmarketing%20experience%20with%20Prevnar%2020.)

> “Blood and lymphatic system disorders: Lymphadenopathy localized to the region of the injection site”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=Blood%20and%20lymphatic%20system%20disorders%3A,region%20of%20the%20injection%20site)

> “General Disorders and Administration Site Conditions: Vaccination-site dermatitis, vaccination-site pruritus, vaccination-site urticaria”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=General%20Disorders%20and%20Administration%20Site%20Conditions%3A%20Vaccination%2Dsite%20dermatitis%2C%20vaccination%2Dsite%20pruritus%2C%20vaccination%2Dsite%20urticaria)

> “Immune System Disorders: Anaphylactic/anaphylactoid reaction, including shock”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=Immune%20System%20Disorders%3A%20Anaphylactic%2Fanaphylactoid%20reaction%2C%20including%20shock)

> “Skin and Subcutaneous Tissue Disorders: Angioneurotic edema, Erythema multiforme”

Source: [PREVNAR 20: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=15428#:~:text=Skin%20and%20Subcutaneous%20Tissue%20Disorders%3A%20Angioneurotic%20edema%2C%20Erythema%20multiforme)

Note: The label's list also names reactions reported in pediatric populations only (cyanosis, hypotonia, apnea, pallor), which are omitted here.

## Related pages
- [Medical information: Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine): Pneumococcal disease prevention in adults](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults)
- [Indication](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/clinical-trials)
- [Specific populations](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/dosing-and-administration)
- [Guidelines](https://www.evicenter.com/medical-information/prevnar-20--pneumococcal-disease-prevention-in-adults/guidelines)
